Letter: TPMT activity and age in IBD patients – authors' reply
Letter: TPMT activity and age in IBD patients – authors' reply
复制标题
信件：IBD 患者的 TPMT 活动和年龄 – 作者的回复
DOI：
10.1111/j.1365-2036.2012.05052.x
复制
发表时间：
2012
影响因子：
7.6
通讯作者：
X. Roblin
中科院分区：
文献类型：
--
作者：
L. Chouchana;C. Narjoz;P. Beaune;M. Loriot;X. Roblin
1. Chouchana L，Narjoz C，Beaune P，Loriot MA，Roblin X.综述文章：遗传药理学对改善炎症性肠病巯基嘌呤治疗的益处。营养药理学治疗2012; 35：15-36。2. Serpe L，Calvo PL，Muntoni E，et al.大规模健康意大利高加索人群中的硫嘌呤S-甲基转移酶药物遗传学：酶活性差异。药物基因组学2009; 10：1753-65。3. McLeod HL，Krynetski EY，Wilimas JA，Evans WE.与成人相比，新生儿红细胞中多态性巯基嘌呤S-甲基转移酶的活性更高。药物遗传学1995; 5：281-6. 4. B文辉，张文辉.儿童和成人在巯嘌呤治疗期间巯嘌呤甲基转移酶活性和代谢产物形成的差异：合并甲氨蝶呤的可能作用。Ther Drug Monit 2002; 24：351-8. 5. Ferroni MA，Marchi G，Sansone E，et al.意大利人群红细胞、肝脏和肾脏中6-巯基嘌呤甲基化率的变异性。欧洲临床药理学杂志1996; 51：23-9. 6. Grossman AB，Noble AJ，Mamula P，Baldassano RN. 6岁及以下炎症性肠病患者对6-巯基嘌呤和硫唑嘌呤的剂量需求增加。炎症性肠病2008; 14：750-5。
1. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15–36. 2. Serpe L, Calvo PL, Muntoni E, et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics 2009; 10: 1753–65. 3. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995; 5: 281–6. 4. Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002; 24: 351–8. 5. Ferroni MA, Marchi G, Sansone E, et al. Variability in the rate of 6-mercaptopurine methylation in the erythrocytes, liver and kidney in an Italian population. Eur J Clin Pharmacol 1996; 51: 23–9. 6. Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14: 750–5.